Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases

Proteomics - Clinical Applications

Volumn 2, Issue 12, 2008, Pages 1575-1585

  Linkov, Faina ^a   Ferris, Robert L ^a,b   Yurkovetsky, Zoya ^a   Marrangoni, Adele ^a   Velikokhatnaya, Lyudmila ^a   Gooding, William ^a   Nolan, Brian ^a   Winans, Matthew ^a   Siegel, Eric R ^c   Lokshin, Anna ^a   Stack Jr , Brendan C ^d  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Cytokines; Hepatocyte growth factor; Interleukins; Monocyte induced interferon; Thyroid cancer

Indexed keywords

ALPHA INTERFERON; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; CYTOKINE; DEATH RECEPTOR 5; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 5; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; SCATTER FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; VASCULOTROPIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SEX DIFFERENCE; THYROID CANCER; THYROID DISEASE;

EID: 58449129659     PISSN: 18628346     EISSN: None     Source Type: Journal    
DOI: 10.1002/prca.200780095     Document Type: Article

References (46)

1. Cancer Facts and Figures 2007, American Cancer Society, http://www.cancer.org.
2. Davies, L., Welch, H. G., Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006, 295, 2164-2167.
3. Schneider, A. B., Sarne, D. H., Long-term risks for thyroid cancer and other neoplasms after exposure to radiation. Nat. Clin. Pract. Endocrinol. Metab. 2005, 1, 82-91.
4. Nagataki, S., Nystrom, E., Epidemiology and primary prevention of thyroid cancer. Thyroid 2002, 12, 889-896.
5. Mack, W. J., Preston-Martin, S., Bernstein, L., Qian, D., Lifestyle and other risk factors for thyroid cancer in Los Angeles County females. Ann. Epidemiol. 2002, 12, 395-401.
6. Wingren, G., Hatschek, T., Axelson, O., Determinants of papillary cancer of the thyroid. Am. J. Epidemiol. 1993, 138, 482-491.
7. Basolo, F., Fiore, L., Pollina, L., Fontanini, G. et al., Reduced expression of interleukin 6 in undifferentiated thyroid carcinoma: In vitro and in vivo studies. Clin. Cancer Res. 1998, 4, 381-387.
8. Gharib, H., Goellner, J. R., Johnson, D. A., Fine-needle aspiration cytology of the thyroid. A 12-year experience with 11 000 biopsies. Clin. Lab. Med. 1993, 13, 699-709.
9. Jones, M. K., Management of nodular thyroid disease. The challenge remains identifying which palpable nodules are malignant. BMJ 2001, 323, 293-294.
10. Gharib, H., Goellner, J. R., Fine-needle aspiration biopsy of the thyroid: An appraisal. Ann. Intern. Med. 1993, 118, 282-289.
11. Greaves, T. S., Olvera, M., Florentine, B. D., Raza, A. S. et al., Follicular lesions of thyroid: A 5-year fine-needle aspiration experience. Cancer 2000, 90, 335-341.
12. de los Santos, E. T., Keyhani-Rofagha, S., Cunningham, J. J., Mazzaferri, E. L., Cystic thyroid nodules. The dilemma of malignant lesions. Arch. Int. Med. 1990, 150, 1422-1427.
13. Tee, Y. Y., Lowe, A. J., Brand, C. A., Judson, R. T., Fine-needle aspiration may miss a third of all malignancy in palpable thyroid nodules: A comprehensive literature review. Ann. Surg. 2007, 246, 714-720.
14. Khalid, A. N., Quraishi, S. A., Hollenbeak, C. S., Stack, B. C., Jr., Fine needle aspiration biopsy vs. ultrasound-guided fine needle aspiration biopsy: Cost-effectiveness as a frontline diagnostic modality for solitary thyroid nodules. Head and Neck Surgery 2008, 30, 1035-1039.
15. Ghoneim, C., Soula-Rothhut, M., Blanchevoye, C., Martiny, L. et al., Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion. J. Biol. Chem. 2007, 282, 15490-15497
16. Borrello,M. G., Alberti, L., Fisher, A., Degl'innocenti, D. et al., Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene. Proc. Natl. Acad. Sci. 2005, 102, 14825-14830.
17. Ruggeri, R. M., Villari, D., Simone, A., Scarfi, R. et al., Coexpression of interleukin-6 (IL-6) and interleukin-6 receptor (IL-6R) in thyroid nodules is associated with co-expression of CD30 ligand/CD30 receptor. J. Endocrinol. Invest. 2002, 25, 959-966.
18. Niedźwiecki, S., Stepień, T., Kopeć, K., Kuzdak, K. et al., Angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and Tie-2 (a receptor tyrosine kinase) concentrations in peripheral blood of patients with thyroid cancers. Cytokine 2006, 36, 291-295,
19. Vesely, D., Astl, J., Lastůvka, P., Matucha, P. et al., Serum levels of IGF-I, HGF, TGF beta 1, bFGF and VEGF in thyroid gland tumors. Physiol. Res. 2004, 53, 83-89.
20. Phan, H. T., Jager, P. L., van derWal, J. E., Sluiter,W. J. et al., The follow-up of patients with differentiated thyroid cancer and undetectable thyroglobulin (Tg) and Tg antibodies during ablation. Eur. J. Endocrinol. 2008, 158, 77-83.
21. Fujarewicz, K., Jarzab, M., Eszlinger, M., Krohn, K. et al., A multi-gene approach to differentiate papillary thyroid carcinoma from benign lesions: Gene selection using support vector machines with bootstrapping. Endocr. Relat. Cancer 2007, 14, 809-826.
22. Pang, S., Smith, J., Onley, D., Reeve, J. et al., A comparability study of the emerging protein array platforms with established ELISA procedures. J. Immunol. Methods 2005, 302, 1-12.
23. Sanchez-Carbayo, M., Antibody arrays: Technical considerations and clinical applications in cancer. Clin. Chem. 2006, 52, 1651-1659.
24. van Belle, G. (Ed.), Statistical Rules of Thumb, John Wiley & Sons, New York 2002, pp. 221.
25. Hathaway, B., Landsittel, D. P., Gooding, W., Whiteside, T. L. et al., Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. Laryngoscope 2005, 115, 522-527.
26. Vignali, D. A., Multiplexed particle-based flow cytometric assays. J. Immunol. Methods 2000, 243, 243-255.
27. Simchen, C., Lehmann, I., Sittig, D., Steinert, M., Aust, G., Expression and regulation of regulated on activation, normal T cells expressed and secreted in thyroid tissue of patients with Graves' disease and thyroid autonomy and in thyroid-derived cell populations. J. Clin. Endocrinol. Metab. 2000, 85, 4758-4764.
28. Younes, M. N., Yazici, Y. D., Kim, S., Jasser, S. A. et al., Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer. Clin. Cancer Res. 2006, 3425-3434.
29. Hoelting, T., Siperstein, A. E., Clark, O. H., Duh, Q. Y., Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo. J. Clin. Endocrinol. Metab. 1994, 79, 401-408.
30. Hébrant, A., van Staveren,W. C., Delys, L., Solis, D.W. et al., Long-term EGF/serum-treated human thyrocytes mimic papillary thyroid carcinomas with regard to gene expression. Exp. Cell. Res. 2007, 313, 3276-3284.
31. Basolo, F., Fiore, L., Pollina, L., Fontanini, G. et al., Reduced expression of interleukin in undifferentiated thyroid carcinoma: In vitro and in vivo studies. Clin. Cancer Res. 1998, 4, 381-387.
32. Zubelewicz, B., Muc-Wierzgoń, M., Wierzgoń, J., Romanowski, W. et al., Genetic disregulation of gene coding tumor necrosis factor alpha receptors (TNF alpha Rs) in follicular thyroid cancer-preliminary report. J. Biol. Regul. Homeost. Agents 2002, 16, 98-104.
33. Scarpino, S., Stoppacciaro, A., Ballerini, F., Marchesi, M. et al., Papillary carcinoma of the thyroid: Hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am. J. Pathol. 2000, 156, 831-837.
34. Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: Biological effects of HGF in thyroid cancer cells depend on Met expression levels. Endocrinology 2004, 145, 4355-4365.
35. Trovato, M., Villari, D., Bartolone, L., Spinella, S. et al., Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules. Thyroid 1998, 8, 125-131.
36. Couch, M. E., Ferris, R. L., Brennan, J. A., Koch, W. M. et al., Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer. Clin. Cancer Res. 2007, 13, 7199-7206.
37. Linkov, F., Lisovich, A., Yurkovetsky, Z., Marrangoni, A. et al., Early detection of head and neck cancer: Development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol. Biomarkers Prev. 2007, 16, 102-107.
38. Wang, J., Seethala, R. R., Zhang, Q., Gooding, W. et al., Autocrine and Paracrine Chemokine Receptor 7 (CCR7) Activation in Head and Neck Cancer: Implications for therapy. J. Nat. Cancer Inst. 2008, 100, 502-512.
39. Kemp, E. H., Metcalfe, R. A., Smith, K. A., Woodroofe, M. N. et al., Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clin. Endocrinol. (Oxf) 2003, 59, 207-213.
40. Newman, T. B., Browner, W. S., Cummings, S. R., in: Hulley, S. B. Cummings, S. R., Browner, W. S., Grady, D., Hearst, N. (Eds.), Designing Clinical Research, Lippincott Williams & Wilkins, Philadelphia, PA 2001, pp. 175-194.
41. Maruvada, P., Srivastava, S., Joint National Cancer Institute-Food and Drug Administration workshop on research strategies, study designs, and statistical approaches to biomarker validation for cancer diagnosis and detection. Cancer Epidemiol. Biomarkers Prev. 2006, 15, 1078-1082.
42. Baker, S. G., The central role of receiver operating characteristic (ROC) curves in evaluating tests for the early detection of cancer. J. Natl. Cancer Inst. 2003, 95, 511-515.
43. Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A. et al., Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD initiative. Clin. Chem. 2003, 49, 1-6.
44. McShane, L. M., Altman, D. G., Sauerbrei,W., Taube, S. E. et al., Reporting recommendations for tumor marker prognostic studies. J. Clin. Oncol. 2005. 23, 9067-9072.
45. Kattan, M. W., Judging new markers by their ability to improve predictive accuracy. J. Natl. Cancer Inst. 2003, 95, 634-635.
46. Somorjai, R. L., Dolenko, B., Baumgartner, R., Class prediction and discovery using gene microarray and proteomics mass spectroscopy data: Curses, caveats, cautions. Bioinformatics 2003, 19, 1484-1491.